Grufity logo
Grufity logo
GRPH

GRPH - Graphite Bio, Inc. Stock Price, Fair Value and News

$137.000.00 (0.00%)
Delayed as of 14 Sep 2026, 04:00 pm ET

10/100

GRPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

GRPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GRPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GRPH Price Action

Last 7 days

15.1%

Last 30 days

117.5%

Last 90 days

124.6%

Trailing 12 Months

87.7%

GRPH RSI Chart

GRPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GRPH Valuation

Market Cap

4.3B

Price/Earnings (Trailing)

-34.16

Price/Sales (Trailing)

200.45

EV/EBITDA

-43.47

Price/Free Cashflow

-37.62

GRPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GRPH Fundamentals

GRPH Revenue

Revenue (TTM)

21.5M

Rev. Growth (Yr)

9.72%

Rev. Growth (Qtr)

188.58%

GRPH Earnings

Earnings (TTM)

-126.0M

Earnings Growth (Yr)

-114.04%

Earnings Growth (Qtr)

23.07%

GRPH Profitability

EBT Margin

-460.63%

Return on Equity

-57.47%

Return on Assets

-53.26%

Free Cashflow Yield

-2.66%

GRPH Investor Care

Shares Dilution (1Y)

10.25%

Diluted EPS (TTM)

-4.13

Revenue & Growth

How Graphite Bio, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202621.0M21.5M--
2025-16.4M17.7M19.1M
2022---15.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Graphite Bio, Inc.

GRPH
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEhttps://graphitebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES120

Graphite Bio, Inc. Frequently Asked Questions

GRPH is the stock ticker symbol of Graphite Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Graphite Bio, Inc. is 4.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, GRPH's PE ratio (Price to Earnings) is -34.16 and Price to Sales (PS) ratio is 200.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GRPH PE ratio will change depending on the future growth rate expectations of investors.